Evidence map›Paper›PMID 32114507›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2020

Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions.

Mingqing Chen, Shuiying Hu, Yang Li, Alice A Gibson, Qiang Fu, Sharyn D Baker, Alex Sparreboom

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mingqing ChenExperimental Cancer Pharmacology Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Shuiying HuExperimental Cancer Pharmacology Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Yang LiExperimental Cancer Pharmacology Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Alice A GibsonExperimental Cancer Pharmacology Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Qiang FuExperimental Cancer Pharmacology Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Sharyn D BakerExperimental Cancer Pharmacology Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Alex SparreboomExperimental Cancer Pharmacology Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio sparreboom.1@osu.edu.
The Ohio State University · US

Funding

The Chesapeake-Ohio Pharmacokinetics Core for The ETCTNU24CA247648 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Mitch A Phelps · 2020 to 2026
$3.6M
Tyrosine kinase inhibitors for the treatment of childhood AMLR01CA138744 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SHARYN D · 2010 to 2019
$3.3M
Prevention of paclitaxel-induced peripheral neuropathy with nilotinibR01CA238946 · NCI · OHIO STATE UNIVERSITY · PI HU, SHUIYING, LUSTBERG, MARYAM B. · 2019 to 2023
$2.9M
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeuticsR01CA215802 · NCI · OHIO STATE UNIVERSITY · PI PABLA, NAVJOT, SPARREBOOM, ALEXANDER · 2017 to 2021
$2.5M
Solute Carriers and Oxaliplatin NeurotoxicityR01CA187176 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SPARREBOOM, ALEXANDER · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA138744NCI NIH HHS R01 CA187176NCI NIH HHS R01 CA215802NCI NIH HHS R01 CA238946NCI NIH HHS U24 CA247648
6 · The paper itself

Abstract

The organic anion transporting polypeptide (OATP)2B1 is localized on the basolateral membrane of hepatocytes and is expressed in enterocytes. Based on its distribution pattern and functional similarity to OATP1B-type transporters, OATP2B1 might have a role in the absorption and disposition of a range of xenobiotics. Although several prescription drugs, including hydroxymethylglutaryl-coenzyme A-CoA reductase inhibitors (statins) such as fluvastatin, are OATP2B1 substrates in vitro, evidence supporting the in vivo relevance of this transporter remains limited, and most has relied on substrate-inhibitor interactions resulting in altered pharmacokinetic properties of the victim drugs. To address this knowledge deficit, we developed and characterized an Oatp2b1-deficient mouse model and evaluated the impact of this transporter on the absorption and disposition of fluvastatin. Consistent with the intestinal localization of Oatp2b1, we found that the genetic deletion or pharmacological inhibition of Oatp2b1 was associated with decreased absorption of fluvastatin by 2- to 3-fold. The availability of a viable Oatp2b1-deficient mouse model provides an opportunity to unequivocally determine the contribution of this transporter to the absorption and drug-drug interaction potential of drugs. SIGNIFICANCE STATEMENT: The current investigation suggests that mice deficient in Oatp2b1 provide a valuable tool to study the in vivo importance of this transporter. In addition, our studies have identified novel potent inhibitors of OATP2B1 among the class of tyrosine kinase inhibitors, a rapidly expanding class of drugs used in various therapeutic areas that may cause drug-drug interactions with OATP2B1 substrates.

Indexed as

Administration, OralAnimalsDrug InteractionsFemaleFluvastatinHEK293 CellsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntestinal AbsorptionIntestinal MucosaMaleMiceMice, KnockoutOrganic Anion TransportersRNAFluvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsOrganic Anion TransportersRNARNA, recombinantSLCO2B1 protein, humanSlco2b1 protein, mouse

Identifiers

PMID32114507
PMCPMC7180048
OpenAlexW3007227522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.